Disease Detail

ID DOID:1240
Name leukemia
Definition A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.
Source DiseaseOntology.org
Alt Ids DOID:9145
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PDGFRA H650Q Imatinib leukemia sensitive detail...
FLT3 act mut Pexidartinib leukemia sensitive detail...
PTPN11 E76K U0126 leukemia sensitive detail...
PTPN11 E76K PD98059 leukemia sensitive detail...
KRAS mutant Trametinib leukemia predicted - sensitive detail...
NRAS mutant Trametinib leukemia predicted - sensitive detail...
RUNX1-RUNX1T1 I-CBP112 leukemia sensitive detail...
KMT2A rearrange Doxorubicin + I-CBP112 leukemia predicted - sensitive detail...
KMT2A rearrange I-CBP112 + JQ1 leukemia predicted - sensitive detail...
RUNX1-RUNX1T1 I-CBP112 + JQ1 leukemia sensitive detail...
RUNX1-RUNX1T1 Doxorubicin + I-CBP112 leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L Pexidartinib leukemia sensitive detail...
FLT3 exon 14 ins Pexidartinib leukemia sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Pexidartinib leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 M837G FLT3 S838R FLT3 D839H Pexidartinib leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 S652G Pexidartinib leukemia predicted - resistant detail...
FLT3 exon 14 ins FLT3 D835H Pexidartinib leukemia resistant detail...
TP53 mutant RG7112 leukemia decreased response detail...
Unknown unknown TAK-960 leukemia not applicable detail...
Unknown unknown YW3-56 leukemia not applicable detail...
KMT2A-MLLT10 EPZ004777 leukemia sensitive detail...
FLT3 exon 14 ins E6201 leukemia sensitive detail...
FLT3 D835G E6201 leukemia sensitive detail...
FLT3 D835Y E6201 leukemia sensitive detail...
FLT3 exon 14 ins FLT3 F691L E6201 leukemia sensitive detail...
FLT3 exon 14 ins FLT3 Y842C E6201 leukemia sensitive detail...
FLT3 ITD FLT3 N676D FLT3 Y842C E6201 leukemia sensitive detail...
KIT N822K Ponatinib leukemia sensitive detail...
FGFR1 rearrange AZD4547 leukemia sensitive detail...
KMT2A-AFF1 IRAK1/4 leukemia sensitive detail...
KMT2A-MLLT3 IRAK1/4 leukemia sensitive detail...
Unknown unknown Carboplatin + Topotecan + Veliparib leukemia not applicable detail...
Unknown unknown P10 + Vorinostat leukemia not applicable detail...
KMT2A-GAS7 AMI-408 leukemia sensitive detail...
Unknown unknown DCBCI0901 leukemia not applicable detail...
KMT2A-AFF1 I-BET151 + SGC0946 leukemia sensitive detail...
NPM1 mutant EPZ004777 leukemia predicted - sensitive detail...
FLT3 exon 14 ins NPM1 mutant MI-503 leukemia predicted - sensitive detail...
FLT3 exon 14 ins NPM1 mutant EPZ004777 leukemia predicted - sensitive detail...
KMT2A-MLLT3 MI-503 leukemia sensitive detail...
Unknown unknown GNE-272 leukemia not applicable detail...
ALK negative CEP-28122 leukemia resistant detail...
NRAS mutant Alpelisib + Binimetinib leukemia sensitive detail...
NRAS mutant Belvarafenib leukemia sensitive detail...
FLT3 exon 14 ins GMI-1359 leukemia predicted - sensitive detail...
FLT3 exon 14 ins GMI-1359 + Sorafenib leukemia predicted - sensitive detail...
FLT3 exon 14 ins FN-1501 leukemia sensitive detail...
Unknown unknown MC180295 leukemia not applicable detail...
FLT3 D835Y CG-806 leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 D835Y CG-806 leukemia predicted - sensitive detail...
FLT3 exon 14 ins FLT3 F691L CG-806 leukemia predicted - sensitive detail...
Unknown unknown H8F4 CAR-T cells leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00620633 Phase I ATA520 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation Active, not recruiting
NCT00777036 Dasatinib A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib Active, not recruiting
NCT01396499 Phase I Buparlisib Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias Completed
NCT01703572 Phase I Brontictuzumab A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Completed
NCT01751425 Phase II Ruxolitinib Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Active, not recruiting
NCT01787487 Phase III Azacitidine Ruxolitinib Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Recruiting
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting
NCT02499861 Phase Ib/II Decitabine + Genistein Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies Completed
NCT02512926 Phase I Cyclophosphamide Carfilzomib Etoposide Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Recruiting
NCT02569476 Phase I BGB-3111 + Obinutuzumab BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies Active, not recruiting
NCT02786485 Phase I Rimiducid BPX-501 Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn
NCT02932280 Phase Ib/II Neratinib Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Recruiting
NCT03229200 FDA approved Ibrutinib Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation